Apoptosis: Targets in pancreatic cancer

Molecular Cancer

Volumn 2, Issue , 2003, Pages

  Westphal, Sabine ^a   Kalthoff, Holger ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Apoptosis; Oncologic therapies; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; CISPLATIN; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LIPOXYGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN SYNTHASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE; PROTEIN P53; SOMATOMEDIN; SURVIVIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN; BIRC5 PROTEIN, HUMAN; GROWTH PROMOTOR; MICROTUBULE ASSOCIATED PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; DRUG PROTEIN BINDING; DRUG TARGETING; GENETIC DISORDER; HOMEOSTASIS; HUMAN; MULTIDRUG RESISTANCE; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ADENOCARCINOMA; PANCREAS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; APOPTOSIS; GROWTH SUBSTANCES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0344858928     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-2-6     Document Type: Review

References (172)

1. Parker SL, Tong T, Bolden S and Wingo PA Cancer statistics. CA Cancer J Clin 1997, 47:5-27
2. Coppola D Molecular prognostic markers in pancreatic cancer. Cancer Contr 2000, 7:421-427
3. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS and Eberlein TJ Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999, 125:73-84
4. Beger HG, Bc̈hler MW and Friess H Surgical results and indications for adjuvant measures in pancreatic cancer. Chirurg 1994, 65:246-252
5. Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M and Büchler MW KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 1996, 56:4876-4880
6. Friess H, Büchler M, Krüger M and Beger HG Treatment of duct carcinoma of the pancreas with the LH-RH-analogue buserelin. Pancreas 1992, 7:516-521
7. Andren-Sandberg A, Bäckman PL and Andersson R Results of adjuvant therapy in resected pancreatic cancer. Int J Pancreatol 1997, 21:31-38
8. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC and Leonard RC Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994, 81:882-885
9. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B and Kalthoff H Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001, 7:925s-932s
10. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and Kalthoff H Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998, 58:1741-1749
11. Igney FH and Krammer PH Death and anti-death: Tumour resistance to apoptosis. Nature Rev Cancer 2002, 2:277-288
12. Miyashita T and Reed JC Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993, 81:151-157
13. Korsmeyer SJ Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80:879-886
14. Hager JH and Hanahan D Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Ann N Y Acad Sci 1999, 887:150-163
15. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y and Nagata S The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
16. Suda T, Takahashi T, Golstein P and Nagata S Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178
17. Krammer PH, Galle PR, Moller P and Debatin KM CD95 (APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res 1998, 75:251-273
18. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH and Walczak H FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609
19. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-1687
20. Zamzami N and Kroemer G The mitochondrion in apoptosis: how Pandora's box opens. Nature Rev Mol Cell Biol 2001, 2:67-71
21. Martinou JC and Green DR Breaking the mitochondrial barrier. Nature Rev Mol Cell Biol 2001, 2:63-67
22. Rathmell JC and Thompson CB The central effectors of cell death in the immune system. Annu Rev Immunol 1999, 17:781-828
23. Nagata S Apoptosis by death factor. Cell 1997, 88:355-365
24. Wyllie AH Apoptosis and carcinogenesis. Eur J Cell Biol 1997, 73:189-197
25. Nagata N and Golstein P The Fas death factor. Science 1995, 267:1449-1456
26. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR and Kratzke RA Human lung carcinomas express Fas ligand. Cancer Res 1997, 57:1007-1012
27. Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, Kakizoe T and Kawabe K Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol 1997, 27:384-388
28. von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH and Moller P Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 1998, 58:526-534
29. Kornmann M, Ishiwata T, Kleeff J, Beger HG and Korc M Fas and Fas-ligand expression in human pancreatic cancer. Ann Surg 2000, 231:368-379
30. von Bernstorff W, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS and Eberlein TJ Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 2002, 94:2552-2560
31. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M and Younes A Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997, 99:618-624
32. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H and Ungefroren H Bcl-xL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-5486
33. Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra SK, Picha KS and Pour PM Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 2001, 7:407-414
34. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162
35. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Biliar TR and Strom SC Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6:564-567
36. Sato T, Irie S, Kitada S and Reed JC FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995, 268:411-415
37. Ungefroren H, Kruse ML, Trauzold A, Roeschmann S, Roeder C, Arlt A, Henne-Bruns D and Kalthoff H FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci 2001, 114:2735-2746
38. Trauzold A, Wermann H, Arlt A, Schẗze S, Schf̈er H, Oestern S, Roeder C, Ungefroren H, Lampe E, Heinrich M, Walczak H and Kalthoff H CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001, 20:4258-4269
39. Adams JM and Cory S The Bcl-2 protein family: Arbiter of cell survival. Science 1998, 281:1322-1326
40. Kelekar A and Thompson CB Bcl-2 family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998, 8:324-330
41. Green DR and Reed JC Mitochondria and apoptosis. Science 1998, 281:1309-1312
42. Gutierrez-Puente Y, Zapata-Benavides P, Tari AM and Lopez-Berestein G Bcl-2 related antisense therapy. Semin Oncol 2002, 29:71-76
43. Evans JD, Cornford PA, Dodson A, Greenhalf W, Foster CS and Neoptolemos JP Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 2001, 1:254-262
44. Campani D, Esposito I, Boggi U, Cecchetti D, Menicagli M, De Negri F, Colizzi L, Del Chiaro M, Mosca F, Fornaciari G and Bevilacqua G Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol 2001, 194:444-450
45. Dias N and Stein CA Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2002, 54:263-269
46. Ehlert JE and Kubbutat MH Apoptosis and its relevance in cancer therapy. Onkologie 2001, 24:433-440
47. Tsujimoto Y Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 1998, 3:697-707
48. Hu Y, Benedict MA, Wu D, Inohara N and Núnez G Bcl-xL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A 1998, 95:4386-4391
49. Xu Z, Friess H, Solioz M, Aebi S, Korc M, Kleeff J and Büchler MW Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001, 94:268-274
50. Shi X, Liu S, Kleeff J, Friess H and Büchler MW Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62:354-362
51. Friess H, Lu Z, Andrén-Sandberg A, Berberat P, Zimmermann A, Adler G, Schmid R and Büchler MW Moderate activation of the apoptosis inhibitor Bcl-xL worsens the prognosis in pancreatic cancer Ann Surg 1998, 228:780-787
52. Hsu YT, Wolter KG and Youle RJ Cytosol-to-membrane redistribution of Bax and Bcl-x(L) during apoptosis. Proc Natl Acad Sci U S A 1997, 94:3668-3672
53. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG and Green DR Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 1999, 274:2225-2233
54. Xu ZW, Friess H, Büchler MW and Solioz M Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 2002, 49:504-510
55. Pirocanac EC, Nassirpour R, Yang M, Wang J, Nardin SR, Gu J, Fang B, Moossa AR, Hoffmann RM and Bouvet M Bax-induction gene therapy of pancreatic cancer. J Surg Res 2002, 106:346-351
56. Seki T, Ohba N, Makino R, Funatomi H and Mitamura K Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene. Anticancer Res 2001, 21:1919-1924
57. Graber HU, Friess H, Zimmermann A, Korc M, Adler G, Schmid R and Bc̈hler MW Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J Gastrointest Surg 1999, 3:74-80
58. Adachi M and Imai K The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2. Cell Death and Differ 2002, 9:1240-1247
59. Baell JB and Huang DC Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 2002, 64:851-863
60. Ding XZ, Tong WG and Adrian TE Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 2001, 1:291-299
61. Tong WG, Ding XZ and Adrian TE The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 2002, 296:942-948
62. Turk B, Stoka V, Rozman-Pungercar J, Cirman T, Droga-Mazovec G, Oreic K and Turk V Apoptotic pathways: involvement of lysosomal proteases. Biol Chem 2002, 383:1035-1044
63. Cryns V and Yuan J Proteases to die for. Genes Dev 1998, 12:1551-1570
64. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ and Williams LT Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997, 278:294-298
65. Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, RD Moir, Goldman RD, Poirier GG, Kaufmann SH and Earnshaw WC Cleavage of lamin A by Mch2a but not CPP32: Multiple interleukin 1-β converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci U S A 1996, 93:8395-8400
66. Thornberry NA and Lazebnik Y Caspases: enemies within. Science 1998, 281:1312-1316
67. Boldin M, Goncharov TM, Goltsev YV and Wallach D Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1-and TNF receptor-induced cell death. Cell 1996, 85:803-815
68. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489
69. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195
70. Krueger A, Baumann S, Krammer PH and Kirchhoff S FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001, 21:8247-8254
71. Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM and Wallach D CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997, 272:19641-4
72. Han DK, Chaudhary PM, Wright ME, Friedmann C, Trask BJ, Riedel RT, Baskin DG, Schwartz SM and Hood L MRIT, a novel death-effector domain-containing protein, interacts with caspases and Bcl-xL and initiates cell death. Proc Natl Acad Sci U S A 1997, 94:11333-8
73. Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Fujimura T, Ninomiya I, Fushida S, Nishimura GI, Shimizu K and Miwa K Human pancreatic cancer cells disable function of Fas receptors at several leels in Fas signal transduction pathway. Int J Oncol 2001, 18:311-316
74. Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M and Tschopp J The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000, 10:640-648
75. Bharti AC and Aggarwal BB Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 2002, 64:883-888
76. Hyer ML, Sudarshan S, Kim Y, Reed JC, Dang JY, Schwartz JY and Norris JS Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther 2002, 1:401-406
77. Kim Y, Suh N, Sporn M and Reed JC An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002, 277:22320-22329
78. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, Susini C and Buscail L Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreas cancer models. Cancer Res 2002, 62:6124-6131
79. Chakrabarty S, Roy M, Hazra B and Bhattacharya RK Induction of apoptosis in human cancer cell lines by diospyrin, a plant-derived bisnaphthoquinoid, and its synthetic derivates. Cancer Lett 2002, 188:85-93
80. Wang W, Waters SJ, MacDonald JR, Roth C, Shentu S, Freeman J, VonHoff DD and Miller AR Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases. Anticancer Res 2002, 22:559-564
81. Birnbaum MJ, Clem RJ and Miller LK An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol 1994, 68:2521-2528
82. Crook NE, Clem RJ and Miller LK An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993, 67:2168-2174
83. Deveraux QL and Reed JC IAP family proteins-suppressors of apoptosis. Genes Dev 1999, 13:239-252
84. Harvey AJ, Soliman H, Kaiser W and Miller LK Anti- and pro-apoptotic activities of baculovirus and Drosophila IAPs in an insect cell line. Cell Death Differ 1997, 4:733-744
85. Deveraux QL, Takahashi R, Salvesen GS and Reed JC X-linked IAP is a direct inhibitor of cell death proteases. Nature 1997, 388:300-303
86. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, GS Salvesen and Reed JC A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998, 273:7787-7790
87. Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnson A, Lefebvre C, Kang X, Salih M, Aubry H, Tamai K, Guan X, Ioannou P, Crawford TO, de Jong PJ, Surh L, Ikeda J-E, Korneluk RG and MacKenzie A The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80:167-178
88. Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R and Zhivotovsky B Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 2002, 279:277-290
89. Hofmann HS, Simm A, Hammer A, Silber RE and Bartling B Expression of inhibitors of apoptosis (IAP) proteins in non-small cell lung cancer. J Cancer Res Clin Oncol 2002, 128:554-560
90. Zhang J, Li Y and Shen B Up-regulation of XIAP by M-CSF is associated with resistance of myeloid leukemia cells to apoptosis. Leukemia 2002, 16:2163-2165
91. McEleny KR, Watson RW, Coffey RN, O'Neill AJ and Fitzpatrick JM Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002, 51:133-140
92. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-583
93. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58:5315-5320
94. Ambrosini G, Adida C and Altieri DC A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921
95. Yamamoto T and Tanigawa N The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001, 34:207-212
96. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M and Altieri DC Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351:882-883
97. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer Cancer Res 1998, 58:5071-5074
98. Lu CD, Altieri DC and Tanigawa N Expression of novel anti-apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998, 58:1808-1812
99. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A and Shimosegawa T Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001, 92:271-278
100. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53
101. Du C, Fang M, Li Y, Li L and Wang X Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42
102. Verhagen AM and Vaux DL Cell death regulation by the mammalian IAP antagonist Diablo/Smac. Apoptosis 2002, 7:163-166
103. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ and Kaufmann SH Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP in situ. J Biol Chem 2002, 277:44236-44243
104. Nowell PC The clonal evolution of tumor cell populations. Science 1976, 194:23-28
105. Porter AC and Vaillancourt RR Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998, 17:1343-1352
106. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M and Beger HG Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the level of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992, 90:1352-1360
107. Chen J and Liu TH Expression of EGF, TGF-alpha, EGFR and c-erbB2 genes and their gene products in human pancreatic carcinoma cell lines. Zentralbl Pathol 1994, 140:265-270
108. Freeman JW, Mattingly CA and Strodel WE Increased tumorigenicity in human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J Cell Physiol 1995, 165:155-163
109. Bergmann U, Funatomi H, Yokoyama M, Berger HG and Korc M Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995, 55:2007-2011
110. Ishiwata T, Bergmann U, Kornmann M, Lopez M, Beger HG and Korc M Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas 1997, 15:367-373
111. Korc M Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998, 7:25-41
112. Arii S, Mori A, Uchida S, Fujimoto K, Shimada Y and Imamura M Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999, 12:25-30
113. Kalthoff H, Roeder C, Gieseking J, Humburg I and Schmiegel W Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A 1993, 90:8972-8976
114. Kalthoff H, Roeder C, Brockhaus M, Thiele HG and Schmiegel W Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. J Biol Chem 1993, 268:2762-2766
115. Schmiegel W, Roeder C, Schmielau J, Rodeck U and Kalthoff H Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A 1993, 90:863-867
116. Grothey A, Voigt W, Schober C, Muller T, Dempke W and Schmoll HJ The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 1999, 125:166-173
117. Prisco M, Romano G, Peruzzi F, Valentinis B and Baserga R Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res 1999, 31:80-89
118. Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W and Kasuga M Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 2002, 24:42-46
119. DeBosch BJ, Deo BK and Kumagai AK Insulin-like growth factor-1 effects on bovine retinal endothelial cell glucose transport: role of MAP kinase. J Neurochem 2002, 81:728-734
120. Nair PN, De Armond DT, Adamo ML, Strodel WE and Freeman JW Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 2001, 20:8203-8214
121. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG and Anderson KC Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21:5673-5683
122. Lopez T and Hanahan D Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002, 1:339-353
123. Ghaneh P, Kawesha A, Evans JD and Neoptolemos JP Topics: Pancreatic cancer-new horizons in diagnosis and treatment: Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002, 9:1-11
124. Shi X, Friess H, Kleeff J, Ozawa F and Büchler MW Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology 2001, 1:517-524
125. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P and Raisch KP Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002, 54:1180-1193
126. Verheul HM and Pinedo HM The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer 2000, 1(Suppl 1):S80-84
127. Sipos B, Weber D, Ungefroren H, Kalthoff H, Zḧlsdorff A, Luther C, Török V and Klöppel G Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: An in vitro and in vivo study. Int J Cancer 2002, 102:592-600
128. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H and Hara N Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000, 60:2169-2177
129. Ogawa T, Takayama K, Takakura N, Kitano S and Ueno H Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002, 9:633-640
130. Derynck R Transforming growth factor alpha. Cell 1988, 54:593-595
131. Webber EM, FitzGerald MJ, Brown PI, Bartlett MH and Fausto N Transforming growth factor-alpha expression during liver regeneration after partial hepatectomy and toxic injury, and potential interactions between transforming growth factor-alpha and hepatocyte growth factor. Hepatology 1993, 18:1422-1431
132. Greten FR, Wagner M, Weber CK, Zechner U, Adler G and Schmid RM TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology 2001, 1:363-368
133. Kanda D, Takagi H, Toyoda M, Horiguchi N, Nakajima H, Otsuka T and Mori M Transforming growth factor alpha protects against Fas-mediated liver apoptosis in mice. FEBS Lett 2002, 519:11-15
134. Schuster N and Kreiglstein K Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 2002, 307:1-14
135. Voss M, Wolff B, Savitskaia N, Ungefroren H, Deppert W, Schmiegel W, Kalthoff H and Naumann M TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol 1999, 14:93-101
136. Ashley DM, Kong FM, Bigner DD and Hale LP Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 1998, 58:302-309
137. Tobin SW, Brown MK, Douville K, Payne DC, Eastman A and Arrick BA Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: the role for Bcl-2. Cell Growth Differ 2001, 12:109-117
138. Shima Y, Nakao K, Nakashima T, Kawakami A, Nakata K, Hamasaki K, Kato Y, Eguchi K and Ishii N Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells. Hepatology 1999, 30:1215-1222
139. Foghi A, Teerds KJ, van der Donk H, Moore NC and Dorrington J Induction of apoptosis in thecal/interstitial cells: action of transforming growth factor (TGF) alpha plus TGF beta on bcl-2 and interleukin-1 beta-converting enzyme. J Endocrinol 1998, 157:489-494
140. Arsura M, Wu M and Sonenshein GE TGF beta 1 inhibits NF-κB/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity 1996, 5:31-40
141. Dijke PT, Goumans M-J, Itoh F and Itoh S Regulation of cell proliferation by Smad proteins. J Cell Phys 2002, 191:1-16
142. Antonello D, Moore PS, Zamboni G, Falconi M and Scarpa A Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer. Cancer Lett 2002, 183:179-183
143. Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ and Hill CS Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. J Biol Chem 2001, 276:43175-43181
144. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH and Goggins M The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001, 7:4115-4121
145. Beg AA and Baltimore D An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996, 274:782-784
146. Karin M, Cao Y, Greten FR and Li ZW NF-κB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002, 2:301-310
147. Karin M and Lin A NF-κB at the crossroads of life and death. Nature Immunol 2002, 3:221-227
148. Bharti AC and Aggarwal BB Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 2002, 64:883-888
149. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE and Schäfer H Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001, 20:859-868
150. Mouria M, Gukovskaya AS, Jung Y, Büchler P, OJ Hines, HA Reber and Pandol SJ Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome c release and apoptosis. Int J Cancer 2002, 98:761-769
151. Ron D and Kazanietz MG New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 1999, 13:1658-1676
152. Trauzold A, Schmiedel S, Sipos B, Wermann H, Westphal S, Roeder C, Klapper W, Arlt A, Lehnert L, Ungefroren H, Johannes F-J and Kalthoff H Overexpression of PKCμ regulates apoptosis and proliferation in pancreatic tumour cells. Submitted
153. van Lint J, Rykx A, Maeda Y, Vantus T, Sturany S, Malhorta V, Vandenheede JR and Seufferlein T Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol 2002, 12:193-200
154. Johannes F-J, Horn J, Link G, Haas E, Siemienski K, Wajant H and Pfizenmaier K Protein kinase Cμ dowregulation of tumor-necrosis-factor-induced apoptosis correlates with enhanced expression of nuclear-factor-κB-dependent protective genes. Eur J Biochem 1998, 257:47-54
155. Datta SR, Brunet A and Greenberg ME Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905-2927
156. Burgering BM and Coffer PJ Protein kinase B (c-Akt) in phosphoinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602
157. Kip1 expression. J Biol Chem 2000, 275:24500-24505
158. Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR and Ohashi PS Protein kinase B regulates T lymphocyte survival, nuclear factor κB activation, and Bcl-X(L) levels in vivo. J Exp Med 2000, 191:1721-1734
159. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR AKT2, a putative oncogene encoding a number of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992, 89:9267-9271
160. Boehle AS, Kurdow R, Boenicke L, Schniewind B, Faendrich F, Dohrmann P and Kalthoff H Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo. Langenbecks Arch Surg 2002, 387:234-239
161. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE and Parsons R Mutation of Pten/Mmac 1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999, 96:1563-1568
162. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M and Mak TW High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998, 8:1169-1178
163. Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H and Korc M Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 2002, 62:5611-5617
164. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ and Streuli CH Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002, 277:27643-27650
165. Kermer P, Ankerhold R, Klocker N, Krajewski S, Reed JC and Bahr M Caspase-9: involvement in secondary death of axotomized rat retinal ganglion cells in vivo. Brain Res Mol Brain Res 2000, 85:144-150
166. Ng SWS, Tsao M-S, Nicklee T and Hedley DW Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human cancer xenografts in immunodeficient mice. Clin Cancer
167. Ng SSW, Tsao MS, Chow S and Hedley DW Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000, 60:5451-5455
168. Ng SS, Tsao MS, Nicklee T and Hedley DW Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001, 7:3269-3275
169. Deppert W, Gohler T, Koga H and Kim E Mutant p53: "gain of function" through perturbation of nuclear structure and function? J Cell Biochem Suppl 2000, 35:115-122
170. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Klöppel G, Kalthoff H, Ungefroren H, Lohr M and Scarpa A Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001, 439:798-802
171. Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR and Neoptolemos JP Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001, 8:199-208
172. Cascallo M, Calbo J, Gelpi JL and Mazo A Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther 2000, 7:545-556